Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average of $2.83

Spero Therapeutics, Inc. (NASDAQ:SPROGet Rating) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.83 and traded as low as $0.81. Spero Therapeutics shares last traded at $0.82, with a volume of 474,644 shares.

Analysts Set New Price Targets

Separately, HC Wainwright reduced their price objective on Spero Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, August 15th.

Spero Therapeutics Stock Down 6.7 %

The stock has a market capitalization of $28.81 million, a price-to-earnings ratio of -0.24 and a beta of 1.87. The business has a 50-day simple moving average of $0.87 and a two-hundred day simple moving average of $2.83.

Institutional Investors Weigh In On Spero Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its position in shares of Spero Therapeutics by 114.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 303,201 shares of the company’s stock valued at $225,000 after acquiring an additional 161,775 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Spero Therapeutics during the 2nd quarter valued at $115,000. Millennium Management LLC lifted its position in shares of Spero Therapeutics by 413.6% during the 2nd quarter. Millennium Management LLC now owns 314,643 shares of the company’s stock valued at $233,000 after acquiring an additional 253,382 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Spero Therapeutics by 760.7% during the 2nd quarter. Renaissance Technologies LLC now owns 939,017 shares of the company’s stock valued at $696,000 after acquiring an additional 829,917 shares during the last quarter. Finally, Kingsbury Capital Investment Advisors LLC acquired a new stake in shares of Spero Therapeutics during the 2nd quarter valued at $45,000. Institutional investors and hedge funds own 57.38% of the company’s stock.

Spero Therapeutics Company Profile

(Get Rating)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

Featured Stories

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.